AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs

23 Feb, 2021

AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs
Photo by Bingnan Li on Unsplash

– AnchorDx announced the completion of a $40m Series C financing round.
– The round was led by OrbiMed and WuXi Huiying Investment.
– The company plans to use the new funds to accelerate the registration and commercialization of its NGS-based products for single-cancer, multi-cancer, and pan-cancer screening and early detection. The company also plans to deploy its technology to other major disease areas.

Asia Biotechnology Emergency Medicine Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: